Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
== Human use == Different parts of the plant are used as traditional remedies for disease and skin afflictions. Juice from the leaves is used to treat warts and snakebite, and the flower is applied to burns. This species has been used as indigenous traditional medicine in Asia for rheumatism, fractures, and other ailments. In Korean folk medicine, this impatiens species is used as a medicine called bongseonhwa dae (봉선화대) for the treatment of constipation and gastritis. Chinese people used the plant to treat those bitten by snakes or who ingested poisonous fish. Juice from the stalk, pulverised dried stalks, and pastes from the flowers were also used to treat a variety of ailments. Vietnamese wash their hair with an extract of the plant to stimulate hair growth. One in vitro study found extracts of this impatiens species, especially of the seed pod, to be active against antibiotic-resistant strains of Helicobacter pylori. It is also an inhibitor of 5α-reductases, enzymes that converts testosterone to dihydrotestosterone (active form of testosterone), thus reducing action of testosterone in our body. In Nepal, the balsam leaves are crushed to dye fingernails on the day of Shrawan Sakranti (Shrawan 1). The day is also observed as Luto Faalne Deen (Go Away-Itch Day). Similarly, in China and Korea, the flowers are crushed and mixed with alum to produce an orange dye that can be used to dye fingernails. Unlike common nail varnish, the dye is semi-permanent, requiring dyed nails to grow off over time in order to remove any traces of color.
In 1926, the Canadian biochemist Archibald Macallum noted the resemblance of body fluids such as blood and lymph to seawater; however, the inorganic composition of all cells differ from that of modern seawater, which led Mulkidjanian and colleagues to reconstruct the "hatcheries" of the first cells combining geochemical analysis with phylogenomic scrutiny of the inorganic ion requirements of modern cells. The authors conclude that ubiquitous, and by inference primordial, proteins and functional systems show affinity to and functional requirement for K+, Zn2+, Mn2+, and [PO4]3−. Geochemical reconstruction shows that this ionic composition could not have existed in the ocean but is compatible with inland geothermal systems. In the oxygen-depleted, CO2-dominated primordial atmosphere, the chemistry of water condensates near geothermal fields would resemble the internal milieu of modern cells. Therefore, precellular evolution may have taken place in shallow "Darwin ponds" lined with porous silicate minerals mixed with metal sulfides and enriched in K+, Zn2+, and phosphorus compounds.
Bush was engaged to Cathryn Lee Wolfman in 1967, but the engagement did not last. Bush and Wolfman remained on good terms after the end of the relationship. While Bush was at a backyard barbecue in 1977, friends introduced him to Laura Welch, a schoolteacher and librarian. After a three-month courtship, she accepted his marriage proposal and they wed on November 5 of that year. The couple settled in Midland, Texas. Bush left his family's Episcopal Church to join his wife's United Methodist Church. On November 25, 1981, Laura Bush gave birth to fraternal twin daughters, Barbara and Jenna. Bush describes being challenged by Billy Graham to consider faith in Jesus "Christ as the risen Lord", how he began reading the Bible daily, "surrendering" to "the Almighty", that "faith is a walk" and that he was "moved by God's love".
The mass spectrometry of proteins has long been a useful technique for identifying posttranslational modifications and, more recently, for probing protein structure. Most proteins are difficult to purify in more than milligram quantities, even using the most modern methods. Hence, early studies focused on proteins that could be purified in large quantities, e.g., those of blood, egg white, various toxins, and digestive/metabolic enzymes obtained from slaughterhouses. Many techniques of protein purification were developed during World War II in a project led by Edwin Joseph Cohn to purify blood proteins to help keep soldiers alive. In the late 1950s, the Armour Hot Dog Co. purified 1 kg (= one million milligrams) of pure bovine pancreatic ribonuclease A and made it available at low cost to scientists around the world. This generous act made RNase A the main protein for basic research for the next few decades, resulting in several Nobel Prizes.
== Product pipeline == Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes. In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin. In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market. In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge. The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset. In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors. On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.
Sources: en.wikipedia.org
== Further reading == Juretic, D., 2021. Bioenergetics: a bridge across life and universe. CRC Press. Lehninger, Albert L (1971). Bioenergetics: The Molecular Basis of Biological Energy Transformations (2nd ed.). Addison-Wesley. ISBN 0-8053-6103-0. Nicholls, David G.; Ferguson, Stuart J. (2002). Bioenergetics (3rd ed.). Academic Press. ISBN 0-12-518124-8. Green DE, Zande HD (September 1981). "Universal energy principle of biological systems and the unity of bioenergetics". Proc. Natl. Acad. Sci. U.S.A. 78 (9): 5344–7. Bibcode:1981PNAS...78.5344G. doi:10.1073/pnas.78.9.5344. PMC 348741. PMID 6946475.
120 g acetic acid (60 g/mol, 2.0 mol) was reacted with 230 g ethanol (46 g/mol, 5.0 mol), yielding 132 g ethyl acetate (88 g/mol, 1.5 mol). The yield was 75%. The molar amount of the reactants is calculated from the weights (acetic acid: 120 g ÷ 60 g/mol = 2.0 mol; ethanol: 230 g ÷ 46 g/mol = 5.0 mol). Ethanol is used in a 2.5-fold excess (5.0 mol ÷ 2.0 mol). The theoretical molar yield is 2.0 mol (the molar amount of the limiting compound, acetic acid). The molar yield of the product is calculated from its weight (132 g ÷ 88 g/mol = 1.5 mol). The % yield is calculated from the actual molar yield and the theoretical molar yield (1.5 mol ÷ 2.0 mol × 100% = 75%).
== Mechanism of antimicrobial activity == The general rule of the mechanism triggering cathelicidin action, like that of other antimicrobial peptides, involves the disintegration (damaging and puncturing) of cell membranes of organisms toward which the peptide is active. Cathelicidins rapidly destroy the lipoprotein membranes of microbes enveloped in phagosomes after fusion with lysosomes in macrophages. Therefore, LL-37 can inhibit the formation of bacterial biofilms.
Peter Giles later called it one of Fripp's "cute political moves". According to Michael Giles, his brother had become disillusioned with the band's lack of success and departed before Fripp ever made this suggestion.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。